The Bcl-xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma

作者：Vasiljevic Natasa; Andersson Kristin; Bjelkenkrantz Kaj; Kjellstrom Christer; Mansson Henrik; Nilsson Elise; Landberg Goran; Dillner Joakim; Forslund Ola^*

来源：International Journal of Cancer, 2009, 124(10): 2361-2366.

DOI：10.1002/ijc.24197

• keratoacanthoma
• squamous cell carcinoma
• HPV
• apoptosis
• proliferation
• Bcl-xL

Keratoacanthoma (KA) is difficult to histologically distinguish from squamous cell carcinoma (SCC). Therefore, although KA is a benign self-resolving skin lesion, KA is commonly treated as SCC. Biomarkers to distinguish KA and SCC would thus be desirable. In search for specific markers, paraffin-embedded tissue samples from 25 SCC and 64 KA were arranged in a tissue microarray (TMA) and stained for immunologic cell-markers CD3, CD20 and CD68 as well as for proteins considered of relevance in tumorgenesis, namely NFKB/p65, I kappa B-alpha, sTAT3, p53, TRAP-1, pRB, phosphorylated pRb, Cyld, p21, p16(INK4), Survivin, Bcl-xL, Caspase 3, Bak, FLK-1/VEGF-r2 and Ki-67. In addition, the tumors were tested for presence of human papillomavirus by PCR. We detected that the two lesions differed significantly in expression of Bcl-xL which was present in 84% of the SCC compared with only 15% in the KA (p < 0.001). The lower expression of the antiapoptotic protein Bel-xL in KA is consistent with a possible role of apoptosis in the regression of KA.

• 出版日期2009-5-15